# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...
BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast c...